Cited by 174Retinoids in leukemia and cellular processesPeroxisome Proliferator-Activated ReceptorsCancer, Lipids, and Metabolism

Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR

Open access
Schug, Thaddeus T., Berry, Daniel C., Toshkov, Illia A., Cheng, Le, Nikitin, Alexander Yu, Noy, Noa·2008·Proceedings of the National Academy of Sciences

Abstract

Retinoic acid (RA) displays potent anticarcinogenic activities that are mediated by the nuclear retinoic acid receptors (RARs). However, use of RA in oncology is limited by RA resistance acquired during carcinogenesis. Moreover, in some cancers, RA facilitates rather than inhibits growth. A clue to this paradoxical behavior was recently suggested by the findings that RA also activates PPARβ/δ, a receptor involved in mitogenic and anti-apoptotic activities. The observations that partitioning of RA between its two receptors is regulated by two intracellular lipid-binding proteins—CRABP-II, which targets RA to RAR, and FABP5, which delivers it to PPARβ/δ—further suggest that RA resistance may stem from the deregulation of the binding proteins, resulting in activation of PPARβ/δ rather than RAR. Here, we show that, in the RA-resistant mouse model of breast cancer MMTV-neu , RA indeed activates the nonclassical RA receptor PPARβ/δ. This behavior was traced to an aberrantly high intratumor FABP5/CRABP-II ratio. Decreasing this ratio in mammary tissue diverted RA from PPARβ/δ to RAR and suppressed tumor growth. The data demonstrate the existence of a mechanism that underlies RA resistance in tumors, indicate that CRABP-II functions as a tumor suppressor, and suggest that the inhibition of FABP5 may comprise a therapeutic strategy for overcoming RA resistance in some tumors.

Integrity signals

Registry

Crossref · 10.1073/pnas.0709981105

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • RA binding activates the nuclear translocation of FABP5, which then delivers the ligand to the PPARβ/δ subtype (but not to the other PPARs).

    “Most interestingly, RA binding activates the nuclear translocation of FABP5, which then delivers the ligand to the PPAR ␤ / ␦ subtype (but not to the other PPARs) (21)(22)(23).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schug, T. T., Berry, D. C., Toshkov, I. A., Cheng, L., Nikitin, A. Y., & Noy, N.
Affiliations
  • Cornell University (US)
  • Case Western Reserve University (US)
Venue
Proceedings of the National Academy of Sciences
Published
2008-05-27
Volume
105
Issue
21
Pages
7546-7551
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2093995222
Cited by
172
References
45
Citations by year
2026: 1 · 2025: 3 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 15 · 2013: 10 · 2012: 7
FWCI
5.35
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (CA107013)
  • National Cancer Institute (R01CA096823, R01 CA 96823, R01CA107013, T32CA009682)
  • National Center for Research Resources (CA96823, K26RR017595)
  • Institute of Genetics
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
retinoic acid resistance, PPARδ, retinoic acid receptor, breast cancer, FABP5, CRABP2, lipid-binding proteins, tumor suppressor, retinoic acid signaling, breast cancer treatment
MeSH terms
Animals, Antineoplastic Agents, Carcinoma, Disease Models, Animal, Mice, Transgenic, Neoplasm Proteins, Transcription, Genetic, Tretinoin, Mammary Neoplasms, Animal, Receptors, Retinoic Acid, Drug Resistance, Neoplasm, Cell Line, Tumor, PPAR delta, PPAR-beta, Fatty Acid-Binding Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review